Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers; Strategic Agreement Expands Vir Portfolio With Three Clinical Stage Assets In Areas Of High...
Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers; Strategic Agreement Expands Vir Portfolio With Three Clinical Stage Assets In Areas Of High...
Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers; Strategic Agreement Expands Vir Portfolio With Three Clinical Stage Assets In Areas Of High Unmet Need
Vir Biotechnology宣佈與賽諾菲簽訂全球獨家許可協議，涉及多個潛在的臨床階段最佳T細胞參與者；戰略協議擴大了Vir產品組合，在未滿足的高需求領域增加了三種臨床階段資產
– License of proprietary masking platform further strengthens Vir's drug discovery capabilities in oncology and infectious disease –
— 專有掩蔽平台的許可進一步增強了Vir在腫瘤學和傳染病領域的藥物發現能力—
– Strategic agreement expands Vir portfolio with three clinical stage assets in areas of high unmet need –
— 戰略協議擴大了Vir的投資組合，在未滿足的高需求領域增加了三項臨床階段資產—
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) with potential applications in a range of cancers and exclusive use of the proprietary PRO-XTENTM masking platform for oncology and infectious disease. Key employees from Sanofi with extensive scientific and development expertise in TCEs, and in-depth experience using the PRO-XTEN platform, will join Vir. Further information about the TCEs and their respective development plans will be provided at Vir's upcoming R&D Day in November.
維爾生物技術有限公司（納斯達克股票代碼：VIR）今天宣佈，在1976年《哈特-斯科特-羅迪諾反壟斷改進法》規定的等待期到期後，於2024年8月1日宣佈的與賽諾菲簽訂的全球獨家許可協議已經結束。該協議爲Vir提供了三種臨床階段的掩膜T細胞接合器（TCE）的全球獨家許可，這些受體可能應用於一系列癌症，並獨家使用專有的Pro-XtentTM掩蔽平台用於腫瘤學和傳染病。賽諾菲在TCE方面擁有豐富科學和開發專業知識以及使用PRO-XTEN平台的豐富經驗的關鍵員工將加入Vir。有關TCE及其各自發展計劃的更多信息，將在Vir即將於11月舉行的研發日上提供。
譯文內容由第三人軟體翻譯。